نتایج جستجو برای: dyslipidemias

تعداد نتایج: 7881  

2017
Hiroshi Koriyama Hironori Nakagami Tomohiro Katsuya Ryuichi Morishita

Journal: :Medical research archives 2022

Type 2 diabetes (T2D) has increased dramatically in the last 20 years afflicting more than 425 million people all over world with 34 located US, emphasizing need for strategic therapies including dietary prescriptions or other lifestyle changes to reduce these numbers. In addition abnormally high plasma glucose levels, concentrations of glycosylated hemoglobin and insulin resistance, T2D is als...

Journal: :The Journal of the Association of Physicians of India 2016
S S Iyengar Raman Puri S N Narasingan S K Wangnoo V Mohan J C Mohan Anoop Misra Usha Sriram Jamshed J Dalal Rajeev Gupta D Prabhakar Prafulla Kerkar Abdul Hamid Zargar Ravi R Kasliwal Rahul Mehrotra Soumitra Kumar Rabin Chakraborty Manoj Chadha Mradul Kumar Daga Krishna Seshadri Justin Paul Narasaraju Kavalipati Dheeraj Kapoor V S Narain Ashu Rastogi A Muruganathan Ajay Gupta S Murthy Neil Bordoloi Prasant Kumar Sahoo Rajesh Kumar Agarwal Milan Chag Rajesh Rajput Rashida Patanwala Melinkeri

251. Efficacy and safety of LDL-lowering therapy among men and women: Meta-analysis of individual data from174 000 participants in 27 randomised trials. The Lancet

Journal: :Revista espanola de cardiologia 2017
L Pérez de Isla Leopoldo Pérez de Isla Pedro Luis Sánchez Fernández Luis Álvarez-Sala Walther Vivencio Barrios Alonso Almudena Castro Conde Enrique Galve Basilio Luis García Ortiz Pedro Mata López Eduardo Alegría Ezquerra Alberto Cordero Fort Juan Cosin Sales Carlos Escobar Cervantes Xavier García-Moll Marimón Juan José Gómez Doblas Domingo Marzal Martín Nekane Murga Eizagaechevarria Carmen de Pablo Zarzosa Luis Miguel Rincón Juan Sanchis Forés José Alberto San Román Calvar Fernando Alfonso Manterola Fernando Arribas Ynsaurriaga Arturo Evangelista Masip Ignacio Ferreira González Manuel Jiménez Navarro Francisco Marín Ortuño Luis Rodríguez Padial Pedro Luis Sánchez Fernández Alessandro Sionis Green Rafael Vázquez García

Authors/Task Force Members: Željko Reiner* (ESC Chairperson) (Croatia) Alberico L. Catapano* (EAS Chairperson)* (Italy), Guy De Backer (Belgium), Ian Graham (Ireland), Marja-Riitta Taskinen (Finland), Olov Wiklund (Sweden), Stefan Agewall (Norway), Eduardo Alegria (Spain), M. John Chapman (France), Paul Durrington (UK), Serap Erdine (Turkey), Julian Halcox (UK), Richard Hobbs (UK), John Kjekshu...

2014
Christine E. Dugan Maria Luz Fernandez

Metabolic syndrome (MetS), characterized by central obesity, dyslipidemias, hypertension, and hyperglycemia, impacts 34 percent of the U.S. adult population. MetS has been demonstrated to be affected by dietary components. Data from epidemiological studies and clinical interventions suggest that one or more dairy components might directly affect MetS parameters. For example, calcium has been po...

2018

Liver cancer is the fifth most frequent neoplasm in men and the ninth in women, with 782,000 new cases of cancer diagnosed in 2012, is the second cause of death associated with cancer in the world, with 746,000 deaths in 2012.1 Hepatocellular carcinoma (HCC) is the most common type of liver cancer. It is produced by the transformation of hepatocytes and is common in patients with cirrhosis, con...

2017

The direct link between lipid metabolism alterations and the increase of cardiovascular risk are well documented. Dyslipidemias, including isolated high LDL-c or mixed dyslipidemia, such as those seen in diabetes (hypertriglyceridemia, high LDL-c or low HDL-c), correlate with a significant risk of cardiovascular and cerebrovascular disease worldwide. This review analyzes the current knowledge ...

2011
Helen Vosper

The progression of atherosclerosis remains a major cause of morbidity and mortality. Plaque formation is an immunological response driven by a number of risk factors, and reduction of risk is the primary goal of treatment. The role of LDL-C is well established and statins have proved effective drugs, although the relative risk reduction is only around 30%. The importance of other factors-notabl...

Journal: :PPAR Research 2008
Robert I. Glazer Hongyan Yuan Zhihui Xie Yuzhi Yin

PPARgamma and PPARdelta agonists represent unique classes of drugs that act through their ability to modulate gene transcription associated with intermediary metabolism, differentiation, tumor suppression, and in some instances proliferation and cell adhesion. PPARgamma agonists are used by millions of people each year to treat type 2 diabetes but may also find additional utility as relatively ...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید